Title: Tyrosinemia Type 1 Presenting with Congestive Cardiac Failure
Authors: Dr Snehal Sonune, Dr Punam Uke, Dr Ankita Kamble, Dr Akshay Wanvat, Dr Poonam Mane, Dr Shubham Meshram
DOI: https://dx.doi.org/10.18535/jmscr/v9i9.10
Abstract
Introduction
Tyrosinemia is an autosomal recessive inherited condition characterized by inability of cells to process tyrosine. It is very rare cause of chronic liver diseases in childhood and usually begins in infants less than 6 months of age. However some may present in later childhood. We present a case of Tyrosinemia type 1 who was presented with Congestive Cardiac Failure and was managed successfully.
References
- Morrow G, Tanguay RM. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1. Adv Exp Med Biol. 2017,959:9-21. doi: 10.1007/978-3-319-55780-9 2. PMID: 28755181.
- van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1. Paediatr Drugs. 2019 Dec;21(6):413-426. doi: 10.1007/s40272-019-00364 4. PMID: 31667718; PMCID: PMC6885500.
- Mirani S, Poojari V, Shetty NS, Shah I. Outcome of Tyrosinemia Type 1 in Indian Children. J Clin Exp Hepatol. 2021 Jan-Feb;11(1):9-13. doi: 10.1016/j.jceh.2020.07.002. Epub 2020 Jul 11. PMID: 33679043; PMCID: PMC7897851.
- Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, Waisbren SE, Gucsavas-Calikoglu M, Wasserstein MP, Coakley K, Scott CR. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017 Dec;19(12). doi: 10.1038/gim.2017.101. Epub 2017 Aug 3. PMID: 28771246; PMCID: PMC5729346.